NSEI:VENUSREM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Venus Remedies Limited, a pharmaceutical company, manufactures and trades in medicines in India and internationally.


Snowflake Analysis

Fair value with imperfect balance sheet.

Share Price & News

How has Venus Remedies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VENUSREM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.9%

VENUSREM

1.1%

IN Pharmaceuticals

0.2%

IN Market


1 Year Return

315.7%

VENUSREM

51.0%

IN Pharmaceuticals

3.3%

IN Market

Return vs Industry: VENUSREM exceeded the Indian Pharmaceuticals industry which returned 49.6% over the past year.

Return vs Market: VENUSREM exceeded the Indian Market which returned 4.3% over the past year.


Shareholder returns

VENUSREMIndustryMarket
7 Day2.9%1.1%0.2%
30 Day77.3%13.4%6.0%
90 Day101.3%24.9%22.4%
1 Year315.7%315.7%53.2%51.0%5.2%3.3%
3 Year11.1%11.1%37.4%33.4%3.2%-1.7%
5 Year-28.2%-28.2%0.1%-3.5%33.2%23.2%

Price Volatility Vs. Market

How volatile is Venus Remedies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Venus Remedies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VENUSREM (₹101.85) is trading below our estimate of fair value (₹378.39)

Significantly Below Fair Value: VENUSREM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VENUSREM is unprofitable, so we can't compare its PE Ratio to the IN Pharmaceuticals industry average.

PE vs Market: VENUSREM is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VENUSREM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VENUSREM is good value based on its PB Ratio (0.4x) compared to the IN Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is Venus Remedies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Venus Remedies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Venus Remedies performed over the past 5 years?

-33.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VENUSREM is currently unprofitable.

Growing Profit Margin: VENUSREM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VENUSREM is unprofitable, and losses have increased over the past 5 years at a rate of 33.8% per year.

Accelerating Growth: Unable to compare VENUSREM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VENUSREM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: VENUSREM has a negative Return on Equity (-4.89%), as it is currently unprofitable.


Next Steps

Financial Health

How is Venus Remedies's financial position?


Financial Position Analysis

Short Term Liabilities: VENUSREM's short term assets (₹2.5B) do not cover its short term liabilities (₹2.6B).

Long Term Liabilities: VENUSREM's short term assets (₹2.5B) exceed its long term liabilities (₹1.2B).


Debt to Equity History and Analysis

Debt Level: VENUSREM's debt to equity ratio (57%) is considered high.

Reducing Debt: VENUSREM's debt to equity ratio has reduced from 68.3% to 57% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if VENUSREM has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if VENUSREM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Venus Remedies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VENUSREM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VENUSREM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VENUSREM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VENUSREM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: VENUSREM is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VENUSREM's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Pawan Chaudhary (56 yo)

no data

Tenure

₹6,358,449

Compensation

Mr. Pawan Chaudhary is a Promoter of Venus Remedies Ltd., and serves as its Managing Director and Chief Financial Officer. Mr. Chaudhary has been the Chairman of the Board at Venus Remedies Ltd. since Octo ...


CEO Compensation Analysis

Compensation vs Market: Pawan's total compensation ($USD85.00K) is above average for companies of similar size in the Indian market ($USD48.97K).

Compensation vs Earnings: Pawan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Pawan Chaudhary
Chairmanno data₹6.36m8%
₹ 100.1m
Ashutosh Jain
CEO, Head of Legal13.25yrs₹3.31mno data
Manu Chaudhary
Joint MD13.92yrs₹6.04m9.26%
₹ 116.0m
Peeyush Jain
Deputy MDno data₹3.69m0.00041%
₹ 5.1k
Ajeet Kapoor
Chief General Manager of Accountsno datano datano data
S. Srivastava
Deputy General Manager of Technicalno datano datano data
Neha Kodan
Company Secretary & Compliance Officer9.33yrsno datano data
Manav Soni
Senior Vice President of Plant & Commercial0.58yrno datano data
Kumud Hunda
Chief Operations Officer of Domestic Operationsno datano datano data
Vishal Chauhan
Chief General Manager of Corporate Quality Assurance0.58yrno datano data

0.6yrs

Average Tenure

49.5yo

Average Age

Experienced Management: VENUSREM's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Pawan Chaudhary
Chairmanno data₹6.36m8%
₹ 100.1m
Ashutosh Jain
CEO, Head of Legal13.25yrs₹3.31mno data
Manu Chaudhary
Joint MD13.92yrs₹6.04m9.26%
₹ 116.0m
Peeyush Jain
Deputy MDno data₹3.69m0.00041%
₹ 5.1k
Gilbert Wenzel
Independent Non-Executive Director13.92yrsno datano data
Suresh Chadha
Independent Non-Executive Director13.92yrs₹30.00kno data
Parvindra Chauhan
Independent Non-Executive Director2.5yrs₹8.25kno data
Navdeep Sud
Independent Non-Executive Director0.17yrno datano data

13.3yrs

Average Tenure

53.5yo

Average Age

Experienced Board: VENUSREM's board of directors are seasoned and experienced ( 13.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Venus Remedies Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Venus Remedies Limited
  • Ticker: VENUSREM
  • Exchange: NSEI
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.252b
  • Shares outstanding: 12.34m
  • Website: https://www.venusremedies.com

Location

  • Venus Remedies Limited
  • Plot 51-52, Industrial Area
  • Phase-1
  • Panchkula
  • Haryana
  • 134113
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
526953BSE (Mumbai Stock Exchange)YesEquity SharesININROct 2004
VENUSREMNSEI (National Stock Exchange of India)YesEquity SharesININROct 2004

Biography

Venus Remedies Limited, a pharmaceutical company, manufactures and trades in medicines in India and internationally. The company’s flagship product is Elores, a novel antibiotic adjuvant entity containing ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 19:34
End of Day Share Price2020/08/14 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.